PPCB News & Events

Propanc Biopharma files to sell 15M shares of common stock for holders

Propanc Biopharma announced that a multi-year joint research collaboration agreement has been established with the Universities of Jaen and Granada, Spain. "As we enter an exciting phase for the Company advancing our lead asset, PRP to a Phase 1b, First-In-Human study in advanced cancer patients this year, we are delighted to strengthen our collaboration with our partner universities, specifically Professors Quesada and Marchal and the research team," said James Nathanielsz, Propanc's CEO.

Propanc Biopharma announced highlights of PRP, its lead proenzyme therapy. The company said, "Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game: 85% tumor growth inhibition demonstrated in preclinical pancreatic models; Forces malignant cells to differentiate-attacking cancer at its root; Reduces fibrosis and resistance markers in the tumor microenvironment; Sensitizes resistant tumors to standard chemo-higher efficacy, lower toxicity; Targets cancer stem cells to cut recurrence risk"

Propanc Biopharma announced that management has executed a service agreement with FyoniBio, a German Contract Development Organization, CDO, based in Berlin for establishing and validating a liquid chromatography-mass spectrometry, LC-MS, based pharmacokinetics, PK, assay. The objective is to quantify the Company's lead asset, PRP, consisting of two proenzymes trypsinogen and chymotrypsinogen, as well as their activated enzyme forms trypsin and chymotrypsin from human serum during the Phase 1b, First-In-Human, FIH, study in advanced cancer patients suffering from solid tumors.